NASDAQ:OABI OmniAb (OABI) Stock Forecast, Price & News $4.25 +0.08 (+1.92%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$4.13▼$4.2750-Day Range$3.21▼$4.3152-Week Range$1.91▼$10.50Volume279,000 shsAverage Volume639,582 shsMarket Capitalization$491.30 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media OmniAb MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside135.3% Upside$10.00 Price TargetShort InterestBearish4.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 4 Articles This WeekInsider TradingSelling Shares$230,950 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.37) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 starsMedical Sector803rd out of 1,010 stocksCommercial Physical Research Industry14th out of 16 stocks 3.5 Analyst's Opinion Consensus RatingOmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, OmniAb has a forecasted upside of 135.3% from its current price of $4.25.Amount of Analyst CoverageOmniAb has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.64% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 6.4.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldOmniAb does not currently pay a dividend.Dividend GrowthOmniAb does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OABI. Previous Next 2.0 News and Social Media Coverage News SentimentOmniAb has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for OmniAb this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for OABI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added OmniAb to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OmniAb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $230,950.00 in company stock.Percentage Held by Institutions42.34% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for OmniAb are expected to decrease in the coming year, from ($0.37) to ($0.38) per share.Price to Book Value per Share RatioOmniAb has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OmniAb (NASDAQ:OABI) StockOmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.Read More Receive OABI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter. Email Address OABI Stock News HeadlinesMay 28, 2023 | americanbankingnews.comInsider Selling: OmniAb, Inc. (NASDAQ:OABI) Director Sells $36,450.00 in StockMay 25, 2023 | americanbankingnews.comOmniAb (NASDAQ:OABI) Trading 9% Higher May 29, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 21, 2023 | americanbankingnews.comJohn L. Higgins Sells 50,000 Shares of OmniAb, Inc. (NASDAQ:OABI) StockMay 17, 2023 | finance.yahoo.comOmniAb Launches OmniDeep™ at the PEGS Boston Conference and ExpoMay 16, 2023 | finance.yahoo.comPresident of OmniAb Matthew Foehr Buys 22% More Shares \May 15, 2023 | markets.businessinsider.comSVB Securities Remains a Buy on OmniAb (OABI)May 14, 2023 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts SubstantiallyMay 29, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 13, 2023 | msn.comBenchmark Reiterates OmniAb (OABI) Buy RecommendationMay 11, 2023 | finance.yahoo.comOmniAb Reports First Quarter 2023 Financial Results and Business HighlightsMay 11, 2023 | americanbankingnews.comOmniAb, Inc. (NASDAQ:OABI) Receives $10.00 Consensus PT from BrokeragesMay 9, 2023 | americanbankingnews.comOmniAb (OABI) Scheduled to Post Earnings on ThursdayMay 5, 2023 | finance.yahoo.comOmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor OpinionMay 5, 2023 | americanbankingnews.comHead-To-Head Review: Data Knights Acquisition (NASDAQ:DKDCA) and OmniAb (NASDAQ:OABI)May 1, 2023 | finance.yahoo.comOmniAb to Report First Quarter 2023 Financial Results on May 11April 30, 2023 | americanbankingnews.comHead-To-Head Contrast: OmniAb (NASDAQ:OABI) vs. MaxCyte (NASDAQ:MXCT)April 25, 2023 | finance.yahoo.comOmniAb to Participate in Upcoming Investor Conferences in MayApril 24, 2023 | americanbankingnews.comOmniAb (NASDAQ:OABI) Coverage Initiated by Analysts at BenchmarkApril 21, 2023 | msn.comBenchmark Initiates Coverage of OmniAb (OABI) with Buy RecommendationApril 16, 2023 | americanbankingnews.comAnalyzing OmniAb (NASDAQ:OABI) and Medpace (NASDAQ:MEDP)April 16, 2023 | americanbankingnews.comBrokerages Set OmniAb, Inc. (NASDAQ:OABI) PT at $10.29April 14, 2023 | msn.comCraig-Hallum Initiates Coverage of OmniAb (OABI) with Buy RecommendationApril 14, 2023 | americanbankingnews.comOmniAb (NASDAQ:OABI) Earns Buy Rating from Analysts at Craig HallumApril 10, 2023 | americanbankingnews.comAnalyzing MaxCyte (NASDAQ:MXCT) and OmniAb (NASDAQ:OABI)April 8, 2023 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call TranscriptApril 5, 2023 | finance.yahoo.comOmniAb Full Year 2022 Earnings: Beats ExpectationsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OABI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter. Email Address OABI Company Calendar Last Earnings3/30/2023Today5/29/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OABI CUSIPN/A CIK1846253 Webwww.omniab.com Phone510-250-7800FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$13.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+135.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,330,000.00 Net MarginsN/A Pretax Margin-47.77% Return on Equity-1.76% Return on Assets-0.88% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual Sales$59.08 million Price / Sales8.32 Cash FlowN/A Price / Cash FlowN/A Book Value$2.96 per share Price / Book1.44Miscellaneous Outstanding Shares115,600,000Free FloatN/AMarket Cap$491.30 million OptionableNot Optionable Beta-0.88 Key ExecutivesMr. Matthew W. Foehr (Age 50)Pres, CEO & Director Comp: $909kMr. Charles S. Berkman J.D. (Age 54)Chief Legal Officer & Sec. Comp: $665.83kMr. Kurt A. Gustafson (Age 55)Exec. VP of Fin. & CFO Dr. Bill Harriman Ph.D.Sr. VP of Antibody DiscoveryMs. Marie-Cecile van de Lavoir D.V.M.Ph.D., Sr. VP of Technical Operations & GeneticsDr. Christel Iffland Ph.D.Sr. VP of Antibody TechnologiesDr. Douglas S. Krafte Ph.D. (Age 65)Sr. VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head Ms. Donna Ventura CPASr. VP of Corp. ControllerMore ExecutivesKey CompetitorsMaxCyteNASDAQ:MXCTInotivNASDAQ:NOTVAbsciNASDAQ:ABSISharecareNASDAQ:SHCRAlpine Immune SciencesNASDAQ:ALPNView All CompetitorsInsiders & InstitutionsLegato Capital Management LLCBought 18,590 shares on 5/25/2023Ownership: 0.016%AWH Capital L.P.Bought 415,000 shares on 5/24/2023Ownership: 0.359%John L HigginsSold 9,000 sharesTotal: $36,450.00 ($4.05/share)Ameriprise Financial Inc.Bought 44,854 shares on 5/22/2023Ownership: 0.039%Trivant Custom Portfolio Group LLCBought 22,250 shares on 5/19/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions OABI Stock - Frequently Asked Questions Should I buy or sell OmniAb stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OABI shares. View OABI analyst ratings or view top-rated stocks. What is OmniAb's stock price forecast for 2023? 9 brokerages have issued 1 year price targets for OmniAb's stock. Their OABI share price forecasts range from $6.00 to $13.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price. View analysts price targets for OABI or view top-rated stocks among Wall Street analysts. How have OABI shares performed in 2023? OmniAb's stock was trading at $3.60 at the beginning of 2023. Since then, OABI shares have increased by 18.1% and is now trading at $4.25. View the best growth stocks for 2023 here. When is OmniAb's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our OABI earnings forecast. How were OmniAb's earnings last quarter? OmniAb, Inc. (NASDAQ:OABI) posted its quarterly earnings results on Thursday, March, 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.05. The firm had revenue of $35.35 million for the quarter, compared to the consensus estimate of $24.73 million. What ETF holds OmniAb's stock ? First Trust Multi-Manager Small Cap Opportunities ETF holds 299 shares of OABI stock, representing 0.04% of its portfolio. What is OmniAb's stock symbol? OmniAb trades on the NASDAQ under the ticker symbol "OABI." Who are OmniAb's major shareholders? OmniAb's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.94%), Macquarie Group Ltd. (3.27%), First Sabrepoint Capital Management LP (2.77%), Rice Hall James & Associates LLC (2.44%), William Blair Investment Management LLC (2.38%) and Dimensional Fund Advisors LP (1.67%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr. View institutional ownership trends. How do I buy shares of OmniAb? Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OmniAb's stock price today? One share of OABI stock can currently be purchased for approximately $4.25. How much money does OmniAb make? OmniAb (NASDAQ:OABI) has a market capitalization of $491.30 million and generates $59.08 million in revenue each year. How can I contact OmniAb? OmniAb's mailing address is 65 EAST 55TH STREET 18TH FLOOR, NEW YORK NY, 10022. The official website for the company is www.omniab.com. The company can be reached via phone at 510-250-7800 or via email at investors@omniab.com. This page (NASDAQ:OABI) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OmniAb, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.